Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Bicycle Therapeutics (BCYC) FCF Margin (2018 - 2026)

Bicycle Therapeutics (BCYC) has disclosed FCF Margin for 9 consecutive years, with 7512.74% as the latest value for Q1 2026.

  • For Q1 2026, FCF Margin fell 664099.0% year-over-year to 7512.74%; the TTM value through Mar 2026 reached 364.89%, up 34288.0%, while the annual FY2025 figure was 347.21%, 12326.0% up from the prior year.
  • FCF Margin hit 7512.74% in Q1 2026 for Bicycle Therapeutics, down from 41.54% in the prior quarter.
  • Across five years, FCF Margin topped out at 296.74% in Q2 2023 and bottomed at 7512.74% in Q1 2026.
  • Average FCF Margin over 5 years is 1056.63%, with a median of 612.3% recorded in 2025.
  • Year-over-year, FCF Margin soared 89245bps in 2025 and then plummeted -664099bps in 2026.
  • Bicycle Therapeutics' FCF Margin stood at 378.06% in 2022, then tumbled by -135bps to 887.99% in 2023, then skyrocketed by 70bps to 263.32% in 2024, then soared by 84bps to 41.54% in 2025, then plummeted by -17986bps to 7512.74% in 2026.
  • According to Business Quant data, FCF Margin over the past three periods came in at 7512.74%, 41.54%, and 612.3% for Q1 2026, Q4 2025, and Q3 2025 respectively.